Santhera Completed Share Placement and Raised CHF 54.8 Million
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera Completed Share Placement and Raised CHF 54.8 Million
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN
Liestal, Switzerland, December 2, 2015 -Santhera Pharmaceuticals (SIX: SANN)
successfully completed the placement of shares which was announced yesterday.
Santhera sold 590,000 new shares via a significantly oversubscribed accelerated
bookbuilding process and raised gross proceeds of CHF 54.8 million. The shares
were sold at a price of CHF 93.0 per share, a discount of 4.5% to the volume-
weighted average price of December 1, 2015.
The new shares from the Company's authorized capital were sold by way of a
private placement in Switzerland and abroad in accordance with applicable
securities laws. Following this transaction, the number of issued shares
increased by 590,000 shares to new 6,262,718 shares, representing a 10.40%
increase of the Company's issued share capital. Trading of the new shares on the
SIX Swiss Exchange is expected to commence on December 3, 2015 and the
settlement of the new shares is expected to take place on December 4, 2015.
"The strong interest of new and existing investors is a sign of confidence in
Santhera's potential and provided us with the financial resources to execute our
development, regulatory and commercial activities as planned," said Christoph
Rentsch, Chief Financial Officer.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera's lead product Raxone(®) is authorized in the European Union for the
treatment of Leber's hereditary optic neuropathy (LHON). Santhera develops
Raxone(®)/Catena(®) in two additional indications, Duchenne muscular dystrophy
(DMD) and primary progressive multiple sclerosis (ppMS), and omigapil for
congenital muscular dystrophy (CMD), all areas of high unmet medical need. For
further information, please visit the Company's website www.santhera.com.
Raxone(® )and Catena(® )are trademarks of Santhera Pharmaceuticals.
For further information, contact:
Thomas Meier, PhD, Chief Executive Christoph Rentsch, Chief Financial
Officer Officer
Phone +41 61 906 89 64 Phone +41 61 906 89 65
thomas.meier(at)santhera.com christoph.rentsch(at)santhera.com
US investor contact: US Public Relations contact:
Hans Vitzthum, LifeSci Advisors, LLC Deanne Eagle, Planet Communications
Phone +1 212 915 2568 Phone +1 917 837 5866
hans(at)lifesciadvisors.com deanne(at)planetcommunications.nyc
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
Each of the syndicate banks is acting exclusively for Santhera Pharmaceuticals
Holding AG in connection with the private placement of the shares and for no
other person. They will not regard any other person as their respective client
in relation to the private placement and will neither be responsible nor provide
protection to anyone other than Santhera Pharmaceuticals Holding AG, nor will
they provide advice to anyone other than Santhera Pharmaceuticals Holding AG in
relation to the private placement, the contents of this press release or any
other matter referred to herein.
Important Cautionary Statement
This press release is not for distribution, directly or indirectly, in or into
the United States of America. The shares that are subject of the private
placement have not been and will not be registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or any U.S. state security laws
and may not be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the U.S. Securities
Act. There will be no public offer of the shares in the United States of
America.
The shares that are the subject of the private placement are not being offered
or sold to any person in the United Kingdom, other than to qualified investors
as defined in Section 86(7) of the Financial Services and Markets Act 2000,
being persons falling within Article 2.1(E)(i), (ii) or (iii) of Directive
2003/71/EC of the European Parliament and of the Council dated 4 November 2003
(Prospectus Directive), which includes legal entities which are regulated by the
Financial Services Authority and entities which are not so regulated whose
corporate purpose is solely to invest in securities and who also fall within the
definition of "Investment Professionals" in Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotions) Order 2005 (the "FPO") and
high net worth entities falling within Article 49(2)(a) to (d) of the FPO.
This press release and the information contained herein are not, and under no
circumstances are to be construed as, an advertisement or a public offering of
securities in Canada or any province or territory thereof. Under no
circumstances are this press release and the information contained herein to be
construed as an offer to sell securities or as a solicitation of an offer to buy
securities in any jurisdiction of Canada. Any offer or sale of the securities
described herein in Canada will be made only under an exemption from the
requirements to file a prospectus with the relevant Canadian securities
regulators and only by a dealer properly registered under applicable securities
laws or, alternatively, pursuant to an exemption from the dealer registration
requirement in the relevant province or territory of Canada in which such offer
or sale is made. No securities commission or similar regulatory authority in
Canada has reviewed or in any way passed upon the merits of the investments
described herein and any representation to the contrary is an offence.
# # #
News release ABB:
http://hugin.info/137261/R/1970762/720536.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire
[HUG#1970762]
Unternehmensinformation / Kurzprofil:
Datum: 02.12.2015 - 08:34 Uhr
Sprache: Deutsch
News-ID 436949
Anzahl Zeichen: 8233
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 332 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera Completed Share Placement and Raised CHF 54.8 Million"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
